Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

1.12USD
3 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.12
Open
$1.14
Day's High
$1.14
Day's Low
$1.10
Volume
224,929
Avg. Vol
268,937
52-wk High
$2.80
52-wk Low
$0.71

Select another date:

Sat, Jun 13 2020

BRIEF-AcelRx Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln

* ACELRX PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source: https://bit.ly/2AofqKS Further company coverage:

BRIEF-Melinta Therapeutics To Acquire Tetraphase Pharmaceuticals

* TETRAPHASE PHARMACEUTICALS INC - TERMINATES MERGER AGREEMENT WITH ACELRX TO ENTER INTO MERGER AGREEMENT WITH MELINTA

BRIEF-Acelrx Pharmaceuticals Announces It Will Not Further Revise Its Offer To Acquire Tetraphase

* ACELRX PHARMACEUTICALS ANNOUNCES IT WILL NOT FURTHER REVISE ITS OFFER TO ACQUIRE TETRAPHASE

BRIEF-AcelRx Pharmaceuticals Announces Revised Merger Agreement With Tetraphase

* ACELRX PHARMACEUTICALS ANNOUNCES REVISED MERGER AGREEMENT WITH TETRAPHASE

BRIEF-Tetraphase Says Termination Fee Co May Be Required To Pay AcelRX In Merger Deal Is Increased To $1.4 Mln

* TETRAPHASE - TERMINATION FEE CO MAY BE REQUIRED TO PAY ACELRX UNDER SPECIFIED CIRCUMSTANCES AS SET FORTH IN MERGER AGREEMENT IS INCREASED TO $1.4 MILLION Source: (https://bit.ly/2TI2ZQw) Further company coverage:

BRIEF-AcelRx Pharmaceuticals Announces Revised Merger Agreement With Tetraphase

* ACELRX PHARMACEUTICALS ANNOUNCES REVISED MERGER AGREEMENT WITH TETRAPHASE

BRIEF-Tetraphase Announces Amendment To Merger Agreement With Acelrx Pharmaceuticals For Increased Consideration

* TETRAPHASE ANNOUNCES AMENDMENT TO MERGER AGREEMENT WITH ACELRX PHARMACEUTICALS FOR INCREASED CONSIDERATION

BRIEF-AcelRx Says Grünenthal GmbH Said It Is Exercising Right To Terminate License, Supply Agreement

* ACELRX PHARMACEUTICALS - GRÜNENTHAL GMBH SAID IT IS EXERCISING RIGHT TO TERMINATE LICENSE, SUPPLY AGREEMENT ON OR ABOUT NOV 14, 2020

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-AcelRx Pharmaceuticals Sees Q1 2020 Revenue $400,000

* PRELIMINARY Q1 2020 REVENUES ARE EXPECTED TO BE $0.4 MILLION

Select another date: